SAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives Average Rating of “Moderate Buy” from Analysts

Shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS) have earned a consensus rating of “Moderate Buy” from the eight analysts that are covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, five have given a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $10.50.

A number of research analysts have commented on the stock. Chardan Capital lifted their price objective on shares of SAB Biotherapeutics from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday, March 11th. Weiss Ratings restated a “sell (d)” rating on shares of SAB Biotherapeutics in a research note on Monday, December 29th. Rodman & Renshaw assumed coverage on shares of SAB Biotherapeutics in a research note on Thursday, April 2nd. They issued a “buy” rating and a $13.00 price objective on the stock. Zacks Research lowered shares of SAB Biotherapeutics from a “hold” rating to a “strong sell” rating in a research note on Thursday, March 12th. Finally, HC Wainwright dropped their price objective on shares of SAB Biotherapeutics from $9.00 to $7.00 and set a “buy” rating on the stock in a research note on Tuesday, March 10th.

SAB Biotherapeutics Price Performance

Shares of NASDAQ:SABS opened at $3.76 on Wednesday. The company’s fifty day moving average price is $3.99 and its 200 day moving average price is $3.57. SAB Biotherapeutics has a 12 month low of $1.05 and a 12 month high of $6.60. The company has a debt-to-equity ratio of 0.02, a current ratio of 9.46 and a quick ratio of 9.46. The firm has a market capitalization of $191.57 million, a P/E ratio of -1.62 and a beta of 0.60.

SAB Biotherapeutics (NASDAQ:SABS) last announced its quarterly earnings results on Monday, March 9th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.30). As a group, sell-side analysts predict that SAB Biotherapeutics will post -3.69 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. ADAR1 Capital Management LLC acquired a new position in SAB Biotherapeutics in the third quarter valued at $30,000. Dimensional Fund Advisors LP acquired a new position in SAB Biotherapeutics in the third quarter valued at $32,000. State of Wyoming purchased a new stake in shares of SAB Biotherapeutics in the fourth quarter valued at about $34,000. Virtu Financial LLC purchased a new stake in shares of SAB Biotherapeutics in the third quarter valued at about $40,000. Finally, State Street Corp purchased a new stake in shares of SAB Biotherapeutics in the fourth quarter valued at about $49,000. 7.82% of the stock is currently owned by institutional investors and hedge funds.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.